FDA issues Alar Pharmaceuticals an untitled letter over promotional materials for its investigational ketamine drug, ALA-3000, because they improperly portrayed the unapproved drug as safe and effective.
FDA’s approval of new drugs is increasingly being supported by fewer clinical studies.
FDA issues Alar Pharmaceuticals an untitled letter over promotional materials for its investigational ketamine drug, ALA-3000, because they improperly portrayed the unapproved drug as safe and effective.
FDA’s approval of new drugs is increasingly being supported by fewer clinical studies.
FDA issues an Early Alert after becoming aware that Boston Scientific sent a letter to customers recommending all Imager II Angiographic Catheters be removed from where they are used or sold.
FDA approves Eli Lilly’s Mounjaro (tirzepatide) for lowering the risk of major adverse cardiovascular events.
